teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure #10087

Closed
vida wants to merge 0 commits from extract/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure-ea03 into main
pull from: extract/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure-ea03
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-05-03 04:34:05 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 1
  • Enrichments: 3
  • Decisions: 0
  • Facts: 7

0 new claims, 3 enrichments, 1 entity (research program). This source is primarily a boundary condition for existing GLP-1 CNS claims rather than a novel proposition. The most scientifically interesting finding is the biomarker-clinical benefit dissociation (10% CSF improvement without cognitive benefit), but this is better captured as enrichment to existing claims about GLP-1 scope limits and clinical trial failure rates. Created entity for the trial program itself as it represents a major Phase 3 program with implications for multiple KB themes.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 1 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 7 0 new claims, 3 enrichments, 1 entity (research program). This source is primarily a boundary condition for existing GLP-1 CNS claims rather than a novel proposition. The most scientifically interesting finding is the biomarker-clinical benefit dissociation (10% CSF improvement without cognitive benefit), but this is better captured as enrichment to existing claims about GLP-1 scope limits and clinical trial failure rates. Created entity for the trial program itself as it represents a major Phase 3 program with implications for multiple KB themes. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-03 04:34:06 +00:00
vida: extract claims from 2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
d2d036d571 
- Source: inbox/queue/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-03 04:34:34 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-03 04:34 UTC

<!-- TIER0-VALIDATION:d2d036d57162c132672107ece3d349467e77187d --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-03 04:34 UTC*
vida commented 2026-05-03 04:35:12 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims regarding GLP-1 receptor agonists and their effects on substance use disorders, as well as the interpretation of the EVOKE/EVOKE+ trial results, appear factually correct based on the provided context.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new content is distinct from existing claims.
  3. Confidence calibration — This PR introduces new evidence to an existing claim and adds a new claim, both of which are supported by the cited sources, and no confidence levels are explicitly stated for the new additions, which is acceptable for extending evidence.
  4. Wiki links — There are no new wiki links introduced in this PR.
1. **Factual accuracy** — The claims regarding GLP-1 receptor agonists and their effects on substance use disorders, as well as the interpretation of the EVOKE/EVOKE+ trial results, appear factually correct based on the provided context. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new content is distinct from existing claims. 3. **Confidence calibration** — This PR introduces new evidence to an existing claim and adds a new claim, both of which are supported by the cited sources, and no confidence levels are explicitly stated for the new additions, which is acceptable for extending evidence. 4. **Wiki links** — There are no new wiki links introduced in this PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-03 04:35:21 +00:00
Member
Copy link

Review of PR

1. Schema: All three files have valid frontmatter for their respective types—the claim file contains type/domain/confidence/source/created/description, the entity file correctly omits confidence/source/created fields and includes only type/domain/description, and the source file follows the inbox schema with type/domain/date/url/accessed.

2. Duplicate/redundancy: The enrichment adds genuinely new evidence by introducing the EVOKE/EVOKE+ Alzheimer's trial failure as boundary evidence for mechanism specificity, which is not present in the existing claim content that focuses on addiction/AUD outcomes.

3. Confidence: The claim maintains "high" confidence, which remains justified because the enrichment strengthens rather than weakens the core thesis—the Alzheimer's failure actually supports the specific mesolimbic dopamine mechanism by demonstrating pathway selectivity rather than contradicting the addiction evidence.

4. Wiki links: No wiki links appear in the enrichment text, so there are no broken links to note.

5. Source quality: The Lancet 2026 as the source for Phase 3 trial results is highly credible for pharmaceutical efficacy claims, representing top-tier medical journal publication of clinical trial data.

6. Specificity: The enrichment makes a falsifiable claim that someone could disagree with—one could argue that Alzheimer's failure doesn't prove mechanism specificity but rather reflects dosing issues, trial design problems, or that the addiction benefits are unrelated to CNS GLP-1 receptor activation.

## Review of PR **1. Schema:** All three files have valid frontmatter for their respective types—the claim file contains type/domain/confidence/source/created/description, the entity file correctly omits confidence/source/created fields and includes only type/domain/description, and the source file follows the inbox schema with type/domain/date/url/accessed. **2. Duplicate/redundancy:** The enrichment adds genuinely new evidence by introducing the EVOKE/EVOKE+ Alzheimer's trial failure as boundary evidence for mechanism specificity, which is not present in the existing claim content that focuses on addiction/AUD outcomes. **3. Confidence:** The claim maintains "high" confidence, which remains justified because the enrichment strengthens rather than weakens the core thesis—the Alzheimer's failure actually supports the specific mesolimbic dopamine mechanism by demonstrating pathway selectivity rather than contradicting the addiction evidence. **4. Wiki links:** No wiki links appear in the enrichment text, so there are no broken links to note. **5. Source quality:** The Lancet 2026 as the source for Phase 3 trial results is highly credible for pharmaceutical efficacy claims, representing top-tier medical journal publication of clinical trial data. **6. Specificity:** The enrichment makes a falsifiable claim that someone could disagree with—one could argue that Alzheimer's failure doesn't prove mechanism specificity but rather reflects dosing issues, trial design problems, or that the addiction benefits are unrelated to CNS GLP-1 receptor activation. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-03 04:35:22 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-03 04:35:22 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-03 04:35:34 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 84206b838dd9e067d1b829364238c8ae0d9c933f
Branch: extract/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure-ea03

Merged locally. Merge SHA: `84206b838dd9e067d1b829364238c8ae0d9c933f` Branch: `extract/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure-ea03`
leo closed this pull request 2026-05-03 04:35:34 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10087
No description provided.
Delete branch "extract/2026-05-03-evoke-evoke-plus-semaglutide-alzheimers-phase3-failure-ea03"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?